Timothy W. Odell, MD; Howard Edelstein, MD; Valerie A. Chirurgi, MD; Jon A. Green, MD, PhD
To the Editor: A 1986 placebo-controlled clinical trial (1) showed decreased mortality in patients with the acquired immunodeficiency syndrome (AIDS) who received zidovudine (AZT) for 24 weeks. Subsequent advances in recognizing and treating opportunistic infections, rather than zidovudine, may account for the progressive increase in the longevity of patients with AIDS. However, the absence of placebo-controlled studies precludes assessing the contribution of zidovudine to the increased survival in these patients. We report the cases of four patients with AIDS who survived for prolonged periods after declining treatment with or showing intolerance to zidovudine.
A 45-year-old homosexual man positive for human
Learn more about subscription options.
Register Now for a free account.
Odell TW, Edelstein H, Chirurgi VA, Green JA. Long Survival without Zidovudine in the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med. 1989;111:856. doi: 10.7326/0003-4819-111-10-856_1
Download citation file:
Published: Ann Intern Med. 1989;111(10):856.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only